HomeHealthPolycystic Ovary Syndrome: a new therapeutic track under study

Polycystic Ovary Syndrome: a new therapeutic track under study

Sopk, or polycystic ovary syndrome, affects about 10 % of women, and is one of the main causes of female infertility. Research is studying a new therapeutic track to counteract this hormonal imbalance. A drug could be offered in ten years.

Researchers try to find a remedy for polycystic ovary syndrome, which affects approximately 10% of women.

This hormonal imbalance is accompanied by invalidating symptoms such as acne, hyper-pile, the absence of rules or even infertility. Often late, it is associated with many other health risks.

“Obesity, diabetes, insulinor resistance, with greater neurological cardiovascular risk,” lists Paolo Giacobini, Inseserm Research Director (Lille Neuroscience and Cognition Unit) in the BFMTV microphone.

The suffering of people with sopk

In social networks, women break this taboo as Oumssalem Ghouzam, who behind the pseudo SOA you share moments of their life with this symptom. “At 23, I was diagnosed with Sopk and my first reaction, it was denial, I didn’t tell anyone,” he said in one of his videos.

“I hate myself because I have changed, I hate myself because my body has changed, I hate myself because I don’t feel a woman anymore,” says Audrey (Diario de aka Audrey in Tiktok).

Hope of treatment

Until now, medicine only offers treatments for some of the Sopk symptoms. Now a track is studied to prevent the disease from declare itself. Some scientists think they can block the hormone produced excessively by follicles in the ovaries, the anti -Mlerlerian hormone.

The syndrome is characterized by the presence of numerous follicles (a set of small cells contained in the ovaries) blocked in their development, leads to an overproduction of male hormones, in particular testosterone, which triggers the ovulation cycle and, therefore, affects fertility.

A medication in ten years

“We were able to regulate the ovarian system that made it possible to rebuild normal destruction so as not to have too many candidates for follicles for ovulation and recover ovulations and the possibilities of designing naturally,” said Mickaël Grynber, obstetric gynecologist and service manager at Antoine Beclère (APHP) to our microphone.

A drug could see daylight, but not before ten years, he believes that researchers.

Author: Carla Lead, Corentin Guist’hau and Anatole Bernaudeau with Florent Bascoul
Source: BFM TV

Stay Connected
16,985FansLike
2,458FollowersFollow
61,453SubscribersSubscribe
Must Read
Related News

LEAVE A REPLY

Please enter your comment!
Please enter your name here